Pinnacle Medicines Secures $89 Million to Propel Oral Peptide Therapy Forward Into Clinical Trials Pinnacle Medicines has successfully closed an oversubscribed Series B financing of $89 million to advance its oral peptide therapeutic pipeline into clinical trials focusing on immunology and cardiometabolic diseases.

Pinnacle Medicines Secures $89 Million to Propel Oral Peptide Therapy Forward Into Clinical Trials #United_States #Clinical_Trials #Doylestown #Pinnacle_Medicines #Oral_Peptide